Kanaoka H - Search Results

1

[A Case of Chronic Expanding Hematoma of the Lower Abdomen after Reconstruction of Deep Inferior Epigastric Perforator Flap for Breast Cancer].

Nakajima S, Kittaka N, Taniguchi A, Kanaoka H, Oyama Y, Seto Y, Soma A, Okuno J, Kusama H, Matsui S, Watanabe N, Yoshida K, Honma K, Kurita T, Nakayama T. Nakajima S, et al. Among authors: kanaoka h. Gan To Kagaku Ryoho. 2023 Dec;50(13):1680-1682. Gan To Kagaku Ryoho. 2023. PMID: 38303171 Japanese.

2

Pegfilgrastim-induced vasculitis of the subclavian and basilar artery complicated by subarachnoid hemorrhage in a breast cancer patient: a case report and review of the literature.

Seto Y, Kittaka N, Taniguchi A, Kanaoka H, Nakajima S, Oyama Y, Kusama H, Watanabe N, Matsui S, Nishio M, Fujisawa F, Takano K, Arita H, Nakayama T. Seto Y, et al. Among authors: kanaoka h. Surg Case Rep. 2022 Aug 12;8(1):155. doi: 10.1186/s40792-022-01499-2. Surg Case Rep. 2022. PMID: 35960391 Free PMC article.

3

Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis.

Taniguchi A, Kittaka N, Kanaoka H, Nakajima S, Oyama Y, Seto Y, Soma AI, Kusama H, Watanabe N, Matsui S, Nishio M, Fujisawa F, Nakayama T. Taniguchi A, et al. Among authors: kanaoka h. Anticancer Res. 2022 Dec;42(12):6027-6035. doi: 10.21873/anticanres.16114. Anticancer Res. 2022. PMID: 36456126

4

Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.

Kusama H, Kittaka N, Soma A, Taniguchi A, Kanaoka H, Nakajima S, Oyama Y, Seto Y, Okuno J, Watanabe N, Matsui S, Nishio M, Fujisawa F, Honma K, Tamaki Y, Nakayama T. Kusama H, et al. Among authors: kanaoka h. Breast Cancer. 2023 Nov;30(6):1085-1093. doi: 10.1007/s12282-023-01504-y. Epub 2023 Oct 2. Breast Cancer. 2023. PMID: 37782377

5

Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.

Kanaoka H, Nagahashi M, Atake Y, Hattori A, Bun A, Fukui R, Ozawa H, Fujimoto Y, Higuchi T, Natori K, Imamura M, Murase K, Takatsuka Y, Miyoshi Y. Kanaoka H, et al. Anticancer Res. 2022 Oct;42(10):4867-4878. doi: 10.21873/anticanres.15992. Anticancer Res. 2022. PMID: 36192009

6

Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.

Ozawa H, Higuchi T, Fujimoto Y, Bun A, Fukui R, Kanaoka H, Nagahashi M, Kitajima K, Yamakado K, Miyoshi Y. Ozawa H, et al. Among authors: kanaoka h. Anticancer Res. 2022 Oct;42(10):4813-4824. doi: 10.21873/anticanres.15986. Anticancer Res. 2022. PMID: 36191999

7

Formation of Fibrils by the Periplasmic Molecular Chaperone HdeB from Escherichia coli.

Nakata Y, Kitazaki Y, Kanaoka H, Shingen E, Uehara R, Hongo K, Kawata Y, Mizobata T. Nakata Y, et al. Among authors: kanaoka h. Int J Mol Sci. 2022 Oct 31;23(21):13243. doi: 10.3390/ijms232113243. Int J Mol Sci. 2022. PMID: 36362039 Free PMC article.

8

Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial.

Ota K, Takeuchi T, Kojima Y, Kawaguchi S, Iwatsubo T, Hakoda A, Nishida S, Sasaki S, Kikutani S, Tawa H, Kanaoka H, Osaka N, Takii M, Nakada K, Higuchi K. Ota K, et al. Among authors: kanaoka h. J Gastroenterol. 2021 Aug;56(8):722-731. doi: 10.1007/s00535-021-01801-3. Epub 2021 Jun 22. J Gastroenterol. 2021. PMID: 34155580

9

Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.

Ushio R, Yamamoto M, Miyasaka A, Muraoka T, Kanaoka H, Tamura H, Kaneko A, Izawa A, Hirama N, Teranishi S, Manabe S, Inoue T, Shibata K, Sugiura Y, Kudo M, Kaneko T. Ushio R, et al. Among authors: kanaoka h. Intern Med. 2021 Nov 15;60(22):3593-3598. doi: 10.2169/internalmedicine.6410-20. Epub 2021 Jun 5. Intern Med. 2021. PMID: 34092725 Free PMC article.

10

Is a proton-pump inhibitor necessary after endoscopic submucosal dissection for superficial esophageal neoplasms? A propensity score analysis.

Kanaoka H, Iwatsubo T, Takeuchi T, Kojima Y, Takahashi Y, Hakoda A, Nishida S, Kawaguchi S, Ota K, Shiba M, Higuchi K. Kanaoka H, et al. Therap Adv Gastroenterol. 2020 Nov 24;13:1756284820974908. doi: 10.1177/1756284820974908. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 33281938 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page